Eli Lilly to acquire cancer drug developer
15-05-2018
Bayer collaborates with Loxo Oncology on cancer medicine
16-11-2017
william_potter / iStockphoto.com
American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Loxo Oncology, US Food and Drug Administration, cancer, Bristol-Myers Squibb, Celgene, breakthrough therapy, biopharmaceuticals, acquisition
